Joly, E. & Hudrisier, D. What is trogocytosis and what is its purpose? Nat. Immunol. 4, 815 (2003).
Dance, A. Core concept: cells nibble one another via the under-appreciated process of trogocytosis. Proc. Natl Acad. Sci. USA 116, 17608–17610 (2019).
CAS PubMed PubMed Central Google Scholar
Bettadapur, A., Miller, H. W. & Ralston, K. S. Biting off what can be chewed: trogocytosis in health, infection, and disease. Infect. Immun. 88, e00930-19 (2020).
PubMed PubMed Central Google Scholar
Ahmed, K. A., Munegowda, M. A., Xie, Y. & Xiang, J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol. Immunol. 5, 261–269 (2008).
CAS PubMed PubMed Central Google Scholar
Miyake, K. & Karasuyama, H. The role of trogocytosis in the modulation of immune cell functions. Cells 10, 1255 (2021).
CAS PubMed PubMed Central Google Scholar
Alhajjat, A. M. et al. Trogocytosis as a mechanistic link between chimerism and prenatal tolerance. Chimerism 4, 126–131 (2013).
PubMed PubMed Central Google Scholar
Ford McIntyre, M. S., Young, K. J., Gao, J., Joe, B. & Zhang, L. Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J. Immunol. 181, 2271–2275 (2008).
Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–116 (2019).
CAS PubMed PubMed Central Google Scholar
Cheng, M., Chen, Y., Xiao, W., Sun, R. & Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell Mol. Immunol. 10, 230–252 (2013).
CAS PubMed PubMed Central Google Scholar
Fang, F., Xiao, W. & Tian, Z. NK cell-based immunotherapy for cancer. Semin. Immunol. 31, 37–54 (2017).
Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).
Koehl, U. et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunology 5, e1115178 (2016).
Daher, M., Melo Garcia, L., Li, Y. & Rezvani, K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin. Transl. Immunol. 10, e1274 (2021).
Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181–192.e5 (2018).
CAS PubMed PubMed Central Google Scholar
Caumartin, J. et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 26, 1423–1433 (2007).
CAS PubMed PubMed Central Google Scholar
Nakamura, K. et al. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand. Proc. Natl Acad. Sci. USA 110, 9421–9426 (2013).
CAS PubMed PubMed Central Google Scholar
Domaica, C. I. et al. Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep. 10, 908–915 (2009).
CAS PubMed PubMed Central Google Scholar
Lu, T. et al. Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation. Cancer Immunol. Res. 10, 1229–1241 (2021).
Miner, C. A., Giri, T. K., Meyer, C. E., Shabsovich, M. & Tripathy, S. K. Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive. J. Immunol. 194, 1945–1953 (2015).
Elliott, J. M. & Yokoyama, W. M. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 32, 364–372 (2011).
CAS PubMed PubMed Central Google Scholar
Anfossi, N. et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331–342 (2006).
Bryceson, Y. T. & Long, E. O. Line of attack: NK cell specificity and integration of signals. Curr. Opin. Immunol. 20, 344–352 (2008).
CAS PubMed PubMed Central Google Scholar
Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K. & Kershaw, M. H. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 89, 216–224 (2011).
Hudrisier, D., Aucher, A., Puaux, A. L., Bordier, C. & Joly, E. Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J. Immunol. 178, 3637–3647 (2007).
Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15–22 (2004).
Poorebrahim, M. et al. Counteracting CAR T cell dysfunction. Oncogene 40, 421–435 (2021).
CAS PubMed PubMed Central Google Scholar
Judge, S. J., Murphy, W. J. & Canter, R. J. Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front. Cell. Infect. Microbiol. 10, 49 (2020).
CAS PubMed PubMed Central Google Scholar
Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081–6100.e26 (2021).
Pesce, S. et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J. Allergy Clin. Immunol. 139, 335–346 e333 (2017).
Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).
CAS PubMed PubMed Central Google Scholar
Gill, S. et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119, 5758–5768 (2012).
CAS PubMed PubMed Central Google Scholar
Myers, J. A. et al. Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight 7, e150079 (2022).
PubMed PubMed Central Google Scholar
Simonetta, F., Pradier, A. & Roosnek, E. T-bet and eomesodermin in NK cell development, maturation, and function. Front. Immunol. 7, 241 (2016).
PubMed PubMed Central Google Scholar
Gardiner, C. M. & Finlay, D. K. What fuels natural killers? Metabolism and NK cell responses. Front. Immunol. 8, 367 (2017).
PubMed PubMed Central Google Scholar
O’Brien, K. L. & Finlay, D. K. Immunometabolism and natural killer cell responses. Nat. Rev. Immunol. 19, 282–290 (2019).
Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2018).
Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624–636 (2021).
CAS PubMed PubMed Central Google Scholar
Li, L. et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 3, 4117–4130 (2019).
CAS PubMed PubMed Central Google Scholar
Merino, A. et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J. Clin. Invest. 129, 3770–3785 (2019).
PubMed PubMed Central Google Scholar
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
CAS PubMed PubMed Central Google Scholar
Vivier, E., Nunes, J. A. & Vely, F. Natural killer cell signaling pathways. Science 306, 1517–1519 (2004).
Kirwan, S. E. & Burshtyn, D. N. Killer cell Ig-like receptor-dependent signaling by Ig-like transcript 2 (ILT2/CD85j/LILRB1/LIR-1). J. Immunol. 175, 5006–5015 (2005).
Zenarruzabeitia, O., Vitalle, J., Eguizabal, C., Simhadri, V. R. & Borrego, F. The biology and disease relevance of CD300a, an inhibitory receptor for phosphatidylserine and phosphatidylethanolamine. J. Immunol. 194, 5053–5060 (2015).
留言 (0)